{
    "nct_id": "NCT03319667",
    "official_title": "A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",
    "inclusion_criteria": "Inclusion criteria :\n\n* Multiple myeloma (IMWG criteria).\n* Newly diagnosed multiple myeloma not eligible for transplant due to age (≥ 65 years) or participants < 65 years with comorbidities impacting possibility of transplant.\n* Evidence of measurable disease.\n* Written informed consent.\n\nExclusion criteria:\n\n* Age < 18 years.\n* Prior treatment for multiple myeloma.\n* Any other prior or ongoing disease/health conditions incompatible with the study objectives.\n* Organ function values not met.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ( PS) > 2.\n* Hypersensitivity to the study medications.\n* Pregnant, breastfeeding, or woman of child bearing potential unwilling to use recommended contraception methods.\n* Male participants who disagree to follow the study contraceptive counseling.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}